Palbociclib is a piperazine pyridopyrimidine that acts in the cell cycle machinery. It is a second generation cyclin-dependent kinase inhibitor selected from a group of pyridopyrimidine compounds due to its favorable physical and pharmaceutical properties.
Palbociclib was developed by Pfizer Inc after the discovery that identified the cyclin-dependent kinases as key regulators of cell growth. It was originally FDA approved on March 2015 for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer and its indications were updated in April 2019 to include male patients based on findings from postmarketing reports and electronic health records demonstrating safety and clinical efficacy.
Palbociclib is indicated in combination with letrozole as initial endocrine-based therapy for the treatment of human epidermal growth factor receptor type 2 (HER2)-negative and hormone receptor(HR)-positive tumors in adult patients with advanced/metastatic breast cancer. It is as well approved in combination with fulvestrant in patients with disease progression with prior endocrine therapy.
In the official labeling, the use of palbociclib should be accompanied with either an aromatase inhibition, no restricted to letrozole, as initial endocrine-based therapy in postmenopausal women or in man.
The breast cancer starts as a group of cancer cells that grow into and destroy the nearby breast tissue. This growth can spread into other parts of the body which is called metastasis. According to the location of the cancer cells, it can be categorized in ductal carcinoma and lobular carcinoma. However, other types of breast cancer include inflammatory breast cancer, Paget disease of the breast, triple negative breast cancer non-Hodgkin lymphoma and soft tissue sarcoma. In males, breast cancer is usually treated as the cases of postmenopausal women and almost all the cases are ductal carcinoma.
Institut Bergonié, Bordeaux, France
Centre Léon Berard, Lyon, France
Centro di Riferimento Oncologico (CRO), Via Franco Gallini 2, Aviano, Pordenone, Italy
Saint Luke's Mountain States Tumor Institute, Boise, Idaho, United States
Saint Luke's Mountain States Tumor Institute - Nampa, Nampa, Idaho, United States
Kootenai Cancer Center, Post Falls, Idaho, United States
Centre Hospitalier de l'Universite de Montreal, Montreal, Quebec, Canada
Saddleback Memorial Medical Center, Laguna Hills, California, United States
West Virginia University, Morgantown, West Virginia, United States
Heilig Hartziekenhuis Lier, Lier, Belgium
Medical University Of Gdansk, Gdansk, Poland
Centro Hospitalar do Porto-- Hospital de Santo Antonio, Porto, Portugal
Sibley Memorial Hospital, Washington, District of Columbia, United States
Allegheny Health Network, Pittsburgh, Pennsylvania, United States
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
Site 30, Praha 5, Czechia
Site 3, Tucson, Arizona, United States
Site 5, Los Angeles, California, United States
MedStar Georgetown University Hospital, Washington, District of Columbia, United States
Medstar Washington Hospital Center, Washington, District of Columbia, United States
Yale Cancer Center, New Haven, Connecticut, United States
Johns Hopkins Hospital, Baltimore, Maryland, United States
JPS Health Network, Fort Worth, Texas, United States
Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta, Georgia, United States
Children's Hospital of Alabama, Birmingham, Alabama, United States
Providence Alaska Medical Center, Anchorage, Alaska, United States
UC San Diego Moores Cancer Center, La Jolla, California, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.